Let’s start with a brief overview of the company — how it started and some milestones. Mr. Fried: The company was started back in the Bronze Age, 25 years ago. It was started by its current founder ...

To start things off, I understand Vaxart is researching oral vaccines for COVID-19, norovirus, and influenza. Could you give us an overview of each program and where they are in the development ...

So it’s been a few years since we last spoke. Let’s start with a brief overview and history of the company. Mr. Itescu: Sure. So Mesoblast has been publicly listed both on Nasdaq and the Australian ...

Tell us about the current trends and themes that are most impacting the space, the subsectors, you watch? Dr. Phipps: Sure. My coverage spans a range of biopharma companies, including large-caps such ...

We’ve spoken several times before, but can you just give our readers a brief refresher on the company and how it has evolved over the years? Mr. Do: BioVie is a biotech company that started developing ...

Recently you wrote a wonderful article that was published in Forbes magazine. In the context of an introduction to your coverage, what inspired you to write that piece, and what are some of the main ...

Interview with Ryan Zimmerman, Managing Director and Medical Technology Analyst, BTIG and former Director of Surgery at ...

Tell us briefly about Picard Medical and the history of SynCardia Total Artificial Heart. Mr. Schnegelsberg: Let me start with SynCardia and then go to Picard. SynCardia is a company with a long ...

For readers who are not familiar with SINTX, give us a brief overview of the company and how it evolved into what it is today. Mr. Olson: SINTX was founded on the use of silicon nitride ceramic ...

In the context of an introduction to your coverage, could you define the life sciences space, and discuss how it differs from the biotech or medtech space? Ms. Utterback: The life science companies ...

For readers who may just be hearing about HeartBeam, explain to us what clinical problem you are trying to solve and why hasn’t that been able to be solved with existing cardiac monitoring tools? Mr.

In the context of an introduction to your coverage, how do you evaluate names in the medtech space? Mr. Zimmerman: The lens we look through is consistency of execution, whether internal expectations ...